Want to see VERA full AI Analyst Report?
VERA Stock Chart & Stats
$42.30
-$0.18(-0.43%)
At close: 4:00 PM EST
$42.30
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$19.07 - $56.05
Previous CloseN/A
Volume142.65K
Average Volume (3M)2.07M
Market Cap
$2.76B
Enterprise Value$2.35K
Total Cash (Recent Filing)$596.76M
Total Debt (Recent Filing)$75.03M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume2,662,821
30 Day Avg. Volume2,069,953
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$82.08Price Target Upside94.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.19
Revenue Forecast (FY)$29.55M
Bulls Say, Bears Say
Bulls Say
FDA Accelerated ApprovalAccelerated approval provides a durable commercial foothold and materially de-risks the lead program by enabling a launch in a defined patient population. This creates a structural revenue opportunity, validates clinical strategy, and strengthens negotiating leverage for payers and partners.
Clear Path To Full ApprovalAn agreed earlier eGFR analysis shortens the timeline and reduces regulatory uncertainty for full approval. That structural clarity improves planning for commercialization scale-up, potential label expansion, and reimbursement discussions, increasing long-term probability of broader market access.
Relatively Strong Balance Sheet Leverage ProfileLow debt and a meaningful equity base provide financial flexibility to fund launch activities, additional studies, and manufacturing scale without near-term refinancing pressure. This structural strength reduces insolvency risk and supports strategic options like partnerships or targeted investments.
Bears Say
Pre-revenue With Widening Net LossesSustained pre-revenue status coupled with rapidly expanding net losses indicates prolonged reliance on external funding. Over months this raises dilution risk, constrains reinvestment capacity, and heightens the need to convert approval into durable product revenue to stabilize the business model.
High And Rising Cash BurnSignificant and accelerating operating and free cash flow deficits create a structural financing requirement. Rising burn narrows runway, may force dilutive financings or non-dilutive deals, and can limit resources available for commercial launch, post-marketing studies, and international expansion.
Regulatory Leadership Transition RiskA CRO change during commercialization and a pivotal full-approval push introduces execution risk in regulatory interactions. Continuity and relationships with authorities matter; transition could delay filings or complicate negotiations, impacting the timing and success of long-term approval and market rollout.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $19.07 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $2.76B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.328 by -$0.362.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.58.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 71,782,906 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.328. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.08 (94.04% Upside)
$82.08 (94.04% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 342.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 33.1%
Last 30 Days ▲ 33.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.90%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
VERA Stock 12 Month Forecast
Average Price Target
$82.08
▲(94.04% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
8.94% Insiders
16.99% Mutual Funds
0.37% Other Institutional Investors
53.64% Public Companies and
Individual Investors